Influences of inactivity and indomethacin on soleus phosphatidylethanolamine and size.
Results of previous investigations indicate that muscular prostaglandins (PG) E2 and F2 alpha are biosynthesized during changes in muscular activity and stimulate protein degradation and synthesis, respectively. The results of the present investigation demonstrates a reduction by indomethacin of soleus hypertrophy, which occurred during a one week recovery period following rat hindlimb suspension. While this hypertrophic model evoked significant, rapid increases in soleus myosin and weight in control groups, continuous systemic release of indomethacin (3.5 mg/Kg/day) reduced the gain in soleus weight, Type I and II hypertrophy. Body weights of all groups were not significantly different. Additional analysis found a selective reduction in phosphatidylethanolamine (PE) during soleus atrophy and hypertrophy which were elicited by hindlimb suspension and recovery from suspension, respectively. Indomethacin enhanced PE recovery. Data from previous and present studies support a hypothesis that a change in soleus activity elicits PE catabolism, changes in cytosolic and muscular calcium, in calcium-dependent phospholipase activity, in PG biosynthesis, and in soleus size.
D000818:Animals; D002118:Calcium / Q000378:metabolism; D000252:Calcium-Transporting ATPases / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006984:Hypertrophy; D007103:Immobilization; D007213:Indomethacin / Q000494:pharmacology*; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009133:Muscular Atrophy / Q000378:metabolism; D010714:Phosphatidylethanolamines / Q000378:metabolism*; D011453:Prostaglandins / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains
D005227:Fatty Acids; D010714:Phosphatidylethanolamines; D011453:Prostaglandins; D000252:Calcium-Transporting ATPases; D002118:Calcium; D007213:Indomethacin